Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody

作者: Ka-On Lam , Victor Ho-Fun Lee

DOI: 10.4236/JCT.2012.326116

关键词:

摘要: Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard care. Although surgical resection selected patients may potentially be curative, systemic therapy is only choice treatment for most with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role through multiple well-designed clinical trials yet, optimal use anti-EGFR undefined. This article serves to review available evidence antibodies speculate strategy their uses.

参考文章(51)
G. H. Sato, J. Mendelsohn, J. Polikoff, J. D. Sato, A. D. Le, T. Kawamoto, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Molecular biology & medicine. ,vol. 1, pp. 511- 529 ,(1983)
Gordon Sato, Bonnie Wolf, Tomoyuki Kawamoto, John Mendelsohn, J. Denry Sato, Hideo Masui, Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies Cancer Research. ,vol. 44, pp. 1002- 1007 ,(1984)
R M Shaheen, S A Ahmad, W Liu, N Reinmuth, Y D Jung, W W Tseng, K E Drazan, C D Bucana, D J Hicklin, L M Ellis, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors British Journal of Cancer. ,vol. 85, pp. 584- 589 ,(2001) , 10.1054/BJOC.2001.1936
J. Metges, J. Raoul, N. Achour, O. Capitain, A. Gourlaouen, J. Ramée, J. Egreteau, J. Douillard, S. Traoré, F. Grudé, PANERB study: Panitumumab after cetuximab-based regimen failure. Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.E14000
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609
Hideharu Kimura, Kazuko Sakai, Tokuzo Arao, Tatsu Shimoyama, Tomohide Tamura, Kazuto Nishio, Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor Cancer Science. ,vol. 98, pp. 1275- 1280 ,(2007) , 10.1111/J.1349-7006.2007.00510.X
Emmanuelle Norguet, Laetitia Dahan, Jean Gaudart, Mohamed Gasmi, L’houcine Ouafik, Jean-François Seitz, Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence? Digestive and Liver Disease. ,vol. 43, pp. 917- 919 ,(2011) , 10.1016/J.DLD.2011.06.002
Ami Citri, Yosef Yarden, EGF–ERBB signalling: towards the systems level Nature Reviews Molecular Cell Biology. ,vol. 7, pp. 505- 516 ,(2006) , 10.1038/NRM1962
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135